Printer Friendly

Retail Holdings announces date of distribution of USD9.00 per share.

M2 EQUITYBITES-January 5, 2018-Retail Holdings announces date of distribution of USD9.00 per share

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Retail Holdings NV (OTC:RHDGF) (ReHo) issued on Thursday a further explanation about the payment date of distribution of USD9.00 per share, which is 10 January 2018.

This share distribution reflects about 42% of ReHo's closing stock price on 3 January 2018. As per NASDAQ rules, when a declared distribution amount exceeds 25% of a company's stock price, the date on which that company's shares will begin to trade without the distribution, or ex-distribution date, will be the first business day after the payment date.

Accordingly, since the distribution will exceed 25% of ReHo's share price, NASDAQ will apply the above rule and ReHo expects the ex-dividend date as set by NASDAQ to be 11 January 2018, the first business day after the distribution payment date. Further, shareholders of record on the record date, 4 January 2018 who sell their shares before the ex-distribution date 11 January 2018, will not receive this cash distribution.

A holding company, ReHo has one principal asset, a 54.1% equity interest in Sewko Holdings Limited, the parent company of Singer Asia Limited, a distributor of consumer durable products through public subsidiaries in Bangladesh and India and with a residual equity interest in a similar business in Sri Lanka. It has no other operating activities other than those carried out through Sewko or Singer Asia.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 5, 2018
Words:254
Previous Article:Novartis passes US FDA's breakthrough therapy designation for Promacta for treating severe aplastic anemia (SAA).
Next Article:Cerebrotech Medical wins US FDA clearance for Cerebrotech Visor to detect asymmetry of intracranial fluid volumes during neurological assessment.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters